Supporting Information for

A New Organocatalyzed Michael-Michael Cascade Reaction Generates Highly Substituted Fused Carbocycles

Patrick G. McGarraugh, Stacey E. Brenner

Department of Chemistry, Brooklyn College and the City University Of New York, 2900 Bedford Avenue, Brooklyn, NY 11210, USA

SBrenner@brooklyn.cuny.edu

Contents

General Information	S 1
Preparation of catalysts (1a-e) and starting enals (3b, 3c, 3e)	S1
Preparation of β -ketoesters (9a-c) and characterization (9b-c)	S1
General Procedure for synthesis of carbocycles (10-11, 17-24)	S2
Determination of absolute configurations	S2
Formation and Characterization of alcohol 26	S4
Characterization of carbocycles (10-11, 17-24)	S5
References	S11
¹ H, ¹³ C NMR spectra and HPLC chromatograms	S13


General Information

All chemicals and solvents were purchased from Sigma-Aldrich or Fisher Scientific. ¹H and ¹³C NMR spectra were collected using a Bruker 400 MHz Biospin. The NMR data herein uses the following abbreviations: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, td=triplet of doublets, dt=doublet of triplets. Enantiomeric excesses were determined using a Perkin Elmer Series 200 HPLC with Daicel Chemical Industries, LTD. Chiralpak AD-H (0.46 x 25 cm), Chiralpak OD-H (0.46 x 25 cm), and Chiralpak AS-H (0.46 x 25 cm) columns. Optical rotations were determined using a Jasco P-1020 polarimeter. IR spectra were collected using a Nicolet 6700 FT-IR. High resolution mass spectra were collected using an Agilent 6520 Q-TOF. Flash chromatography was carried out with Merck, grade 9385, 230-400 mesh, 600 Å silica gel and with Merck, silica 60F-254 on glass, 250 µm layer TLC plates with fluorescent indicator. Solvents were dried and kept air free in a solvent purification unit. Solvents were evaporated using a standard rotovapor and a high vacuum. All reactions were carried out in oven dried glassware and conducted under an argon atmosphere.

Preparation of catalysts (1a-e) and starting enals (3b, 3c, 3e)

Catalysts **1a-e**^{1,2} were prepared from the corresponding diarylprolinols³ using known procedures. Noncommercially available enals **3b**, **3c**, and **3e**, were prepared according to a known procedure.⁴


Preparation of β -ketoesters (9a-c) and characterization (9b-c)



The β -ketoester **9a** was prepared using an adapted procedure.⁵ To a two-neck, round-bottom flask equipped with an internal thermometer was added magnesium metal (2.5 g, 103 mmol) and THF (21 mL). Bromoethane (7.5 mL, 100 mmol) was slowly added to this solution while maintaining the internal temperature below 25 °C. The mixture was allowed to stir at room temperature until all the metal had reacted (~1h). The flask was equipped with an outlet and a solution of diisopropylamine (14.2 ml, 100 mmol) in THF (21 mL) was slowly added while maintaining the internal temperature below 25 °C. The mixture was allowed to stir at room temperature for 3h. The temperature of the mixture was lowered to 10 $^{\circ}$ C and a solution of **25a**⁶ (7.0 g, 50 mmol), ethyl acetate (4.90 mL, 50 mmol), and THF (35 mL) was added while maintaining the internal temperature between 10-15 °C. The reaction was allowed to stir at room temperature for 3h and the reaction was poured into 4M H_2SO_4 (aq) with ice. The mixture was extracted three times with Et₂O. The ether extracts were combined, dried over MgSO₄, filtered The mixture was purified via flash chromatography (97/3, petroleum and concentrated. ether/Et₂O) and β -ketoester **9a** was isolated in 70% yield. Characterization of **9a** was in agreement with experimental data.⁵


 β -ketoesters **9b** and **9c** were prepared from **25a**⁶ and **25b**⁷, respectively, using the same procedure and were obtained in similar yields.

9b: methyl 3-cyclopentenyl-3-oxopropanoate



pale yellow oil. IR (thin film, KBr): 2954, 2843, 1747, 1656, 1588, 1445, 1363, 1263, 1209, 1063, 1004, 954, 800, 729 cm⁻¹; ¹H NMR (400 MHz, CDCl₃), keto form: δ 6.79 (m, 1H), 3.73 (s, 3H), 3.71 (s, 2H), 2.59 (m, 4H), 1.95 (quintet, *J* = 7.6 Hz, 2H) ppm, enol form: δ 11.75 (s, 1H), 6.61 (m, 1H), 5.06 (s, 1H), 3.75 (s, 3H), 2.52-2.46 (m, 4H), 1.97 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃), keto and enol form: δ 190.3, 173.5, 168.5, 168.1, 146.1, 145.5, 138.2, 137.6, 88.5, 52.4, 51.3, 46.1, 31.2, 33.6, 31.0, 30.7, 23.2, 22.9 ppm. HRMS (ESI) : [M⁺] calcd for [C₉H₁₂O₃]: 168.0786, found: 168.0790.

9c: ethyl 3-(2,5-dihydrothiophen-3-yl)-3-oxopropanoate



pale yellow oil. IR (thin film, KBr): 2982, 1740, 1675, 1599, 1422, 1252, 1222, 1182, 1034, 797 cm⁻¹; ¹H NMR (400 MHz, CD₃OD), keto form: δ 7.06 (m, 1H), 4.17 (q, *J* = 7.1 Hz, 2H), 4.00 (m, 2H), 3.87 (m, 2H), 3.84 (s, 2H), 1.26 (t, *J* = 7.2 Hz, 3H) ppm, enol form: δ 6.73 (m, 1H), 5.15 (s, 1H), 4.22 (q, *J* = 7.1 Hz, 2H), 3.88-3.82 (m, 4H), 1.28 (t, *J* = 7.2 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃), keto and enol form: δ 189.3, 172.7, 167.0, 166.7, 144.0, 142.2, 136.8, 134.3, 90.0, 61.6, 60.5, 46.9, 39.7, 39.2, 37.0, 36.5, 14.3, 14.2 ppm. HRMS (ESI) : [M⁺] calcd for [C₉H₁₂O₃S]: 200.0507, found: 200.0512.


General Procedure for synthesis of carbocycles (10-11, 17-24)

To an oven dried flask was added catalyst **1a** (32.6 mg, 0.1 mmol), solvent (3.33 mL), β -ketoester **9a** (182.2 mg, 1.0 mmol), and enal **3a** (177.2 mg, 1.0 mmol). The reaction was allowed to stir for the indicated time at room temperature. The reaction mixture was filtered through a plug of silica and concentrated. The percent conversion of the crude reaction mixture could be determined using an internal standard. The diastereomeric mixture of **10a**, **10b** and **11** was then purified via column chromatography (85/15, petroleum ether/Et₂O) and an isolated yield was determined. The diastereomeric ratio of the isolated product was determined through comparison of the relative integrations of the aldehyde and/or enol peaks in the ¹H NMR spectrum. Samples of the pure diastereomers **10a**, **10b** and **11** were obtained through further flash chromatography. Carbocycles **17-24** were prepared and purified using the same procedure.

Racemic samples of the Michael-Michael products **10-11** and **17-24** were prepared in a similar manner using racemic catalyst **1a**.


Determination of absolute configurations

The stereochemistry of 10a at C3 was assigned by analogy to other 1a-catalyzed conjugate additions. The relative configuration of Michael-Michael product 10a was determined via X-ray crystallography.



10a


It was established that **10b** was the *C4* epimer of **10a** by subjecting pure **10a** to **1a** (20 mol %) and benzoic acid (20 mol %) in EtOH (0.3 M), which produced a mixture of **10a** and **10b**. The configurations of Michael-Michael products **17-24a** and **17-24b** were assigned by analogy.




The configuration of **11** was assigned as one of the two structures shown below, using NOE.

An NOE interaction between H_e and H_d was observed indicating that the aldehyde functionality at the *C4* position was *cis* to H_e . The signals for H_b and H_c overlapped completely, complicating further analysis of NOE interactions. However, another NOE interaction was observed between H_a and the overlapping ¹H signals for H_b and H_c . This indicated that the H_a proton was *cis* to either H_b or H_c . Due to the overlapping of the ¹H signals for H_b and H_c , the stereochemistry at *C6* could not be determined from the NOE spectrum of **11**.

Aldehyde **11** was silvlated and reduced to alcohol **26** (see below). The nature of the ring junction in **26** was determined using NOE. An NOE interaction between H_a and H_b was observed indicating that the ring junction in **26** was *cis*. Thus, it was determined that the ring junction in **11** was *cis*, having the configuration shown below.




Formation and Characterization of Alcohol 26



To an oven dried flask was added (±)-**11** (13.0 mg, 36 µmol), CH_2CI_2 (1.4 mL), and TBSCI (11.3 mg, 75 µmol). DBU (11.2 µL, 75 µmol) was added dropwise to the stirring solution of (±)-**11**. The reaction was monitored by TLC and was quenched when (±)-**11** was completely consumed (~1.5 h). The reaction was diluted with CH_2CI_2 (15 mL) and washed with saturated NH_4CI (*aq*) (15 mL). The aqueous layer was washed with CH_2CI_2 (2 x 15 mL). The organic layers were combined, dried over Na_2SO_4 , filtered and concentrated. The silylated intermediate was purified via column chromatography (90/10, petroleum ether/Et₂O) and used in step ii.).

To an oven dried flask was added, the silylated intermediate from step i.) (17.1 mg, 36 µmol) and a 1/1 mixture of MeOH/CH₂Cl₂ (1 mL). The stirring solution was cooled in an ice bath and NaBH₄ (9.5 mg, 252 µmol) was added. The reaction was stirred at 0° C and was monitored by TLC. The reaction was quenched after the silylated intermediate was completely consumed (~30 min). The reaction was diluted with CH₂Cl₂ (15 mL) and washed with saturated NH₄Cl (*aq*) (15 mL). The aqueous layer was washed with CH₂Cl₂ (2 x 15 mL). The organic layers were combined, dried over Na₂SO₄, filtered and concentrated. Alcohol (±)-**26** was purified via column chromatography (80/20, petroleum ether/EtOAc).

26: (3aS,6S,7S,7aS)-ethyl 4-(tert-butyldimethylsilyloxy)-7-(hydroxymethyl)-6-(4-nitrophenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless crystals. m.p.: 135-137 °C. IR (thin film, KBr): 3444, 2956, 2931, 2859, 1704, 1519, 1347, 1255, 1201, 1062, 781, 704 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.5 Hz, 2H), 7.42 (d, *J* = 8.6 Hz, 2H), 4.15 (d, *J* = 9.0 Hz, 1H), 3.87 (m, 1H), 3.72 (m, 1H), 3.65 (dd, *J* = 3.4, 11.1 Hz, 1H), 3.31 (dd, *J* = 2.6, 11.1 Hz, 1H), 2.50 (q, *J* = 8.1 Hz, 1H), 2.38 (m, 1H), 2.14 (m, 1H), 1.74 (m, 3H), 1.51-1.60 (m, 3H), 0.94 (s, 9H), 0.86 (t, *J* = 7.1 Hz, 3H), 0.17 (s, 3H), 0.15 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 167.5, 158.8, 152.9, 146.7, 129.4, 123.5, 112.1, 61.2,

59.9, 45.0, 44.9, 44.6, 38.2, 31.3, 29.9, 25.9, 24.1, 18.5, 14.0, -3.8, -3.8 ppm; HRMS (ESI) : $[M^{+}]$ calcd for $[C_{25}H_{37}NO_6Si]$: 475.2390, found: 475.2390.


Characterization of carbocycles (10-11, 17-24)

10a: (3aR,6S,7R,7aS)-ethyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless crystals. m.p.: 84-86 °C. $[\alpha]_{D}^{23}$ = +177.8 (*c* 1.00, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2962, 2870, 1721, 1650, 1615, 1519, 1348, 1280, 1243, 1213, 855, 826, 706 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.54 (s, 1H), 9.38 (d, *J* = 1.7 Hz, 1H), 8.13 (d, *J* = 8.7 Hz, 2H), 7.26 (d, *J* = 8.7 Hz, 2H), 4.45 (d, *J* = 3.9 Hz, 1H), 4.05 (m, 2H), 2.98 (q, *J* = 8.2 Hz, 1H), 2.59 (m, 2H), 2.32 (m, 1H), 2.06 (m, 1H), 1.80 (m, 1H), 1.59 (m, 2H), 1.33 (m, 1H), 1.07 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 203.2, 176.0, 171.2, 147.8, 147.3, 129.9, 123.6, 99.1, 60.9, 54.5, 43.2, 41.5, 32.5, 31.7, 31.3, 25.0, 14.1 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 99:1), 1.0 mL/min; major enantiomer t_R = 20.7 min, minor enantiomer t_R = 24.8 min. HRMS (ESI) : [M⁻] calcd for [C₁₉H₂₁NO₆]: 359.1369, found: 359.1377.

10b: (3aR,6S,7S,7aS)-ethyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless amorphous solid. $[\alpha]_D^{23}$ = +65.9 (*c* 0.500, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2958, 1721, 1647, 1608, 1519, 1347, 1235, 1109, 853 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.65 (s, 1H), 9.66 (d, *J* = 1.5 Hz, 1H), 8.13 (d, *J* = 8.8 Hz, 2H), 7.38 (d, *J* = 8.8 Hz, 2H), 4.34 (d, *J* = 7.8 Hz, 1H), 3.93 (m, 2H), 3.00 (q, *J* = 6.3 Hz, 1H), 2.79 (m, 1H), 2.57 (m, 1H), 2.07 (m, 1H), 1.98 (m, 1H), 1.71 (m, 3H), 1.55 (m, 1H), 0.87 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 201.2, 174.8, 171.7, 153.1, 146.8, 129.0, 123.7, 98.3, 60.8, 56.3, 43.5, 37.7, 36.9, 29.6. 26.1. 23.9. 13.8 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 99:1), 1.0 mL/min; minor enantiomer t_R = 27.4 min, major enantiomer t_R = 32.3 min. HRMS (ESI) : [M⁻] calcd for [C₁₉H₂₁NO₆]: 359.1369, found: 359.1370.

11: (6S,7S,7aR)-ethyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless crystals. m.p.: 95-97 °C. $[\alpha]_D^{25}$ = +20.1 (*c* 0.500, CH₂Cl₂, 37% ee); IR (thin film, KBr): 2963, 2874, 1725, 1650, 1613, 1519, 1348, 1286, 1228, 855 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.59 (s, 1H), 9.66 (d, *J* = 1.2 Hz, 1H), 8.13 (d, *J* = 8.7 Hz, 2H), 7.31 (d, *J* = 8.7 Hz, 2H), 4.35 (d, *J* = 5.9 Hz, 1H), 3.95 (m, 2H), 2.80 (q, *J* = 7.6 Hz, 1H), 2.58 (m, 2H), 2.29 (m, 1H), 1.52-1.78 (m, 4H), 1.28 (m, 1H), 0.86 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 202.0, 176.1, 171.6, 152.9, 146.7, 128.3, 123.9, 97.1, 60.8, 56.5, 42.0, 39.9, 37.4, 31.0, 29.9, 24.2, 13.9 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 95:5), 1.0 mL/min; major enantiomer t_R = 22.5 min, minor enantiomer t_R = 66.5 min. HRMS (ESI) : [M] calcd for [C₁₉H₂₁NO₆]: 359.1369, found: 359.1370.

17a: (3aR,6S,7R,7aS)-ethyl 6-(4-chlorophenyl)-7-formyl-4-hydroxy-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless amorphous solid. $[\alpha]_{D}^{24}$ = +120.7 (*c* 1.00, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2961, 2871, 1723, 1650, 1616, 1279, 1242, 1213, 1093, 832 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.51 (s, 1H), 9.32 (d, *J* = 2.8 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 2H), 4.31 (d, *J* = 4.9 Hz, 1H), 4.05 (m, 2H), 2.88 (q, *J* = 8.6 Hz, 1H), 2.60 (m, 1H), 2.48 (m, 1H), 2.29 (m, 1H), 2.02 (m, 1H), 1.78 (m, 1H), 1.61 (m, 2H), 1.29 (m, 1H), 1.08 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 204.2, 175.4, 171.5, 138.4, 133.0, 130.2, 128.6, 99.7, 60.8, 54.6, 43.2, 41.0, 32.4, 31.6, 31.3, 25.0, 14.1 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 0.5 mL/min; major enantiomer t_R = 14.3 min, minor enantiomer t_R = 18.7 min. HRMS (ESI) : [M⁺] calcd for [C₁₉H₂₁ClO₄]: 348.1128, found: 348.1129.

17b: (3aR,6S,7S,7aS)-ethyl 6-(4-chlorophenyl)-7-formyl-4-hydroxy-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless oil. $[\alpha]_D^{24}$ = +31.3 (*c* 0.500, CH₂Cl₂, 98% ee); IR (thin film, KBr): 2958, 2874, 1723, 1647, 1613, 1490, 1308, 1235, 1091, 1014, 841 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.59 (s, 1H), 9.68 (d, *J* = 1.7 Hz, 1H), 7.23 (d, *J* = 8.3 Hz, 2H), 7.11 (d, *J* = 8.4 Hz, 2H), 4.19 (d, *J* = 7.0 Hz, 1H), 3.96 (m, 2H), 2.94 (q, *J* = 7.3 Hz, 1H), 2.70 (m, 1H), 2.52 (m, 1H), 2.08 (m, 1H), 1.88 (m, 1H), 1.78-1.87 (m, 4H), 0.92 (t, *J* = 7.2 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 202.5, 174.4, 172.0, 143.3, 132.2, 129.4, 128.6, 98.7, 60.6, 56.5, 43.4, 37.6, 36.7, 29.8, 26.4, 24.1, 13.8 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 0.3 mL/min; major enantiomer t_R = 24.3 min, minor enantiomer t_R = 31.6 min. HRMS (ESI) : [M⁺] calcd for [C₁₉H₂₁ClO₄]: 348.1128, found: 348.1131.

18a: (3aR,6S,7R,7aS)-ethyl 7-formyl-4-hydroxy-6-(3-(trifluoromethyl)phenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless oil. $[\alpha]_{D}^{24}$ = +126.1 (*c* 1.00, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2964, 2872, 1724, 1651, 1618, 1328, 1244, 1165, 1126, 1033, 831, 806, 708 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.52 (s, 1H), 9.34 (d, *J* = 2.6 Hz, 1H), 7.47 (d, *J* = 7.8 Hz, 1H), 7.38 (t, *J* = 7.7 Hz, 1H), 7.32 (s, 1H), 7.28 (d, *J* = 8.5 Hz, 1H), 4.39 (d, *J* = 4.9 Hz, 1H), 4.04 (m, 2H), 2.98 (q, *J* = 8.5 Hz, 1H), 2.62 (m, 1H), 2.53 (m, 1H), 2.31 (m, 1H), 2.05 (m, 1H), 1.79 (m, 1H), 1.63 (m, 2H), 1.07 (m, 1H), 1.05 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 203.8, 175.7, 171.4, 141.2, 132.3, 131.0, 130.7, 128.9, 125.6, 124.1, 99.5, 60.8, 54.6, 43.2, 41.5, 32.5, 31.7, 31.4, 25.0, 14.0 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 0.2 mL/min; major enantiomer t_R = 38.4 min, minor enantiomer t_R = 43.8 min. HRMS (ESI) : [M] calcd for [C₂₀H₂₁F₃O₄]: 382.1392, found: 382.1395.

18b: (3aR,6S,7S,7aS)-ethyl 7-formyl-4-hydroxy-6-(3-(trifluoromethyl)phenyl)-2,3,3a,6,7,7ahexahydro-1H-indene-5-carboxylate




colorless oil. $[\alpha]_D^{23}$ = +18.7 (*c* 1.00, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2962, 2877, 1724, 1648, 1613, 1329, 1236, 1163, 1125, 836, 802, 705 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.63 (s, 1H), 9.68 (d, *J* = 1.8 Hz, 1H), 7.45 (m, 2H), 7.38 (m, 2H), 4.28 (dd, *J* = 7.6, 1.2 Hz, 1H), 3.93 (m, 2H), 2.99 (q, *J* = 6.5 Hz, 1H), 2.78 (m, 1H), 2.55 (m, 1H), 2.07 (m, 1H), 1.95 (m, 1H), 1.57-1.79 (m, 4H), 0.84 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 202.0, 174.6, 171.9, 146.1, 131.4, 131.0, 130.7, 128.9, 125.0, 123.3, 98.6, 60.6, 56.4, 43.4, 37.8, 36.8, 29.6, 26.2, 24.0, 13.6 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 0.3 mL/min; minor enantiomer t_R = 25.3 min, major enantiomer t_R = 30.3 min. HRMS (ESI) : [M⁻] calcd for [C₂₀H₂₁F₃O₄]: 382.1392, found: 382.1395.

19a: (3aR,6S,7R,7aS)-ethyl 7-formyl-4-hydroxy-6-phenyl-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless oil. $[\alpha]_D^{23}$ = +117.4 (*c* 1.00, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2962, 1722, 1648, 1617, 1280, 1243, 1212, 1084, 832, 704 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.54 (s, 1H), 9.32 (d, *J* = 3.0 Hz, 1H), 7.26 (m, 3H), 7.09 (d, *J* = 7.2 Hz, 2H), 4.35 (d, *J* = 4.9 Hz, 1H), 4.07 (m, 2H), 2.97 (q, *J* = 9.4 Hz, 1H), 2.59 (m, 1H), 2.49 (m, 1H), 2.31 (m, 1H), 2.01 (m, 1H), 1.80 (m, 1H), 1.63 (m, 2H), 1.30 (m, 1H), 1.09 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 204.7, 175.3, 171.7, 139.7, 128.9, 128.4, 127.1, 99.9, 60.7, 54.8, 43.2, 41.7, 32.5, 31.6, 31.4, 25.0, 14.1 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 1.0 mL/min; minor enantiomer t_R = 7.0 min, major enantiomer t_R = 8.9 min. HRMS (ESI) : [M⁺] calcd for [C₁₉H₂₂O₄]: 314.1518, found: 314.1520.

19b: (3aR,6S,7S,7aS)-ethyl 7-formyl-4-hydroxy-6-phenyl-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless oil. $[\alpha]_D^{21} = +23.6 (c \, 0.500, CH_2Cl_2, 98\% ee); IR (thin film, KBr): 2958, 2874, 1720, 1646, 1614, 1234, 1096, 1029, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl_3) <math>\delta$ 12.59 (s, 1H), 9.71 (d, *J* = 2.0 Hz, 1H), 7.26 (m, 2H), 7.18 (m, 3H), 4.20 (d, *J* = 6.8 Hz, 1H), 3.95 (m, 2H), 2.93 (q, *J* = 7.7 Hz, 1H), 2.72 (m, 1H), 2.52 (m, 1H), 2.09 (m, 1H), 1.58-1.89 (m, 5H), 0.88 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl_3) δ 203.3, 174.3, 172.2, 144.4, 128.5, 128.0, 126.4, 99.0, 60.5, 56.6, 43.4, 38.4, 36.7, 29.9, 26.5, 24.2, 13.8 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 0.3 mL/min; minor enantiomer t_R = 24.0 min, major enantiomer t_R = 41.4 min. HRMS (ESI) : [M⁺] calcd for [C₁₉H₂₂O₄]: 314.1518, found: 314.1521.

20a: (3aR,6S,7R,7aS)-ethyl 7-formyl-4-hydroxy-6-p-tolyl-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate



colorless oil. $[\alpha]_D^{26}$ = +109.4 (*c* 1.00, CH₂Cl₂, 99% ee); IR (thin film, KBr): 2962, 2870, 1722, 1648, 1401, 1379, 1242, 1212, 1083, 1034, 821 cm⁻¹; NMR (400 MHz, CDCl₃) δ 12.51 (s, 1H), 9.31 (d, *J* = 3.0 Hz, 1H), 7.05 (d, *J* = 7.8 Hz, 2H), 6.95 (d, *J* = 7.8 Hz, 2H), 4.30 (d, *J* = 4.8 Hz, 1H), 4.10 (m, 1H), 3.99 (m, 1H), 2.94 (q, *J* = 8.6 Hz, 1H), 2.65 (m, 1H), 2.44 (m, 1H), 2.29 (s, 3H), 2.29 (m, 1H), 1.99 (m, 1H), 1.77 (m, 1H), 1.60 (m, 2H), 1.27 (m, 1H), 1.09 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 204.9, 175.2, 171.8, 136.7, 136.6, 129.1, 128.8, 100.1, 60.7, 54.9, 43.2, 41.2, 32.5, 31.6, 31.4, 25.1, 21.1, 14.1 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 0.5 mL/min; major enantiomer t_R = 13.0 min, minor enantiomer t_R = 15.1 min. HRMS (ESI) : [M⁻] calcd for [C₂₀H₂₄O₄]: 328.1675, found: 328.1676.


20b: (3aR,6S,7S,7aS)-ethyl 7-formyl-4-hydroxy-6-p-tolyl-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate



colorless oil. $[\alpha]_{D}^{24} = +26.3 (c 0.800, CH_{2}Cl_{2}, 99\% ee)$; IR (thin film, KBr): 2958, 2875, 1721, 1646, 1613, 1307, 1272, 1233, 812 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.58 (s, 1H), 9.71 (d, *J* = 2.2 Hz, 1H), 7.06 (m, 4H), 4.17 (d, *J* = 6.2 Hz, 1H), 3.97 (m, 2H), 2.91 (q, *J* = 7.3 Hz, 1H), 2.68 (m, 1H), 2.51 (m, 1H), 2.30 (s, 3H), 2.10 (m, 1H), 1.58-1.85 (m, 5H), 0.93 (t, *J* = 7.2 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 204.9, 175.2, 171.8, 136.7, 136.6, 129.1, 128.8, 100.1, 60.7, 54.9, 43.2, 41.2, 32.5, 31.6, 31.4, 25.1, 21.1, 14.1 ppm; the enantiomeric excess was determined by


HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 99:1), 0.5 mL/min; major enantiomer t_R = 15.7 min, minor enantiomer t_R = 16.9 min. HRMS (ESI) : [M⁻] calcd for [C₂₀H₂₄O₄]: 328.1675, found: 328.1681.

21a: (3aR,6R,7R,7aS)-ethyl 7-formyl-6-(furan-2-yl)-4-hydroxy-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate




colorless oil. $[\alpha]_D^{23}$ = +58.9 (*c* 1.00, CH₂Cl₂, 98% ee); IR (thin film, KBr): 2963, 2870, 1724, 1648, 1288, 1242, 1081, 834, 741, 599 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.54 (s, 1H), 9.58 (d, *J* = 2.4 Hz, 1H), 7.27 (dd, *J* = 1.8, 0.8 Hz, 1H), 6.24 (dd, *J* = 3.2, 1.9 Hz, 1H), 5.95 (dd, *J* = 2.5, 0.7 Hz, 1H), 4.41 (d, *J* = 4.3 Hz, 1H), 4.16 (m, 2H), 2.86 (q, *J* = 8.9 Hz, 1H), 2.61 (m, 1H), 2.39 (m, 1H), 2.23 (m, 1H), 2.06 (m, 1H), 1.75 (m, 1H), 1.57 (m, 2H), 1.33 (m, 1H), 1.20 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 203.3, 176.2, 171.6, 154.3, 141.9, 110.3, 107.7, 97.8, 60.8, 54.9, 42.8, 34.8, 33.5, 31.8, 31.0, 25.3, 14.2 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 99:1), 0.5 mL/min; major enantiomer t_R = 23.6 min, minor enantiomer t_R = 27.2 min. HRMS (ESI) : [M⁻] calcd for [C₁₇H₂₀O₅]: 304.1311, found: 304.1316.

21b: (3aR,6R,7S,7aS)-ethyl 7-formyl-6-(furan-2-yl)-4-hydroxy-2,3,3a,6,7,7a-hexahydro-1Hindene-5-carboxylate



colorless oil. $[\alpha]_D^{22} = -12.3 (c \ 1.00, CH_2Cl_2, 98\% ee); IR (thin film, KBr): 2961, 2876, 1720, 1647, 1276, 1222, 1086, 1011, 837, 736, 599 cm⁻¹; ¹H NMR (400 MHz, CDCl_3) <math>\delta$ 12.61 (s, 1H), 9.75 (d, J = 1.8 Hz, 1H), 7.29 (d, J = 1.0 Hz, 1H), 6.26 (dd, J = 3.1, 1.8 Hz, 1H), 5.97 (d, J = 3.2 Hz, 1H), 4.32 (d, J = 5.4 Hz, 1H), 4.11 (m, 2H), 2.88 (td, J = 5.4, 2.1 Hz, 1H), 2.83 (q, J = 8.0 Hz, 1H), 2.57 (m, 1H), 2.12 (m, 1H), 1.86 (m, 1H), 1.59-1.77 (m, 4H), 1.12 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl_3) δ 203.0, 175.0, 172.1, 156.4, 141.3, 110.4, 106.5, 96.6, 60.7, 53.4, 43.1, 36.7, 32.9, 30.2, 27.1, 24.5, 14.1 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 99:1), 0.5 mL/min; major enantiomer t_R = 21.5 min, minor enantiomer t_R = 27.6 min. HRMS (ESI) : [M⁻] calcd for [C₁₇H₂₀O₅]: 304.1311, found: 304.1316.


22a: (3aS,4R,5R,7aR)-diethyl 4-formyl-7-hydroxy-2,3,3a,4,5,7a-hexahydro-1H-indene-5,6dicarboxylate



colorless oil. $[\alpha]_D^{24}$ = +30.2 (*c* 1.00, CH₂Cl₂, 98% ee); IR (thin film, KBr): 2979, 2872, 1728, 1652, 1618, 1243, 1189, 1095, 1035, 835 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.47 (s, 1H), 9.78 (d, *J* = 1.5 Hz, 1H), 4.23 (m, 2H), 4.10 (m, 2H), 4.04 (d, *J* = 4.6 Hz, 1H), 2.83 (q, *J* = 9.4 Hz, 1H), 2.68 (m, 1H), 2.36 (m, 1H), 2.18 (m, 2H), 1.75 (m, 1H), 1.58 (m, 2H), 1.37 (m, 1H), 1.29 (t, *J* = 7.1 Hz, 120 (t, *J* = 7.1 Hz), 1.58 (t, J = 7.1 Hz


3H), 1.21 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 201.6, 176.6, 172.0, 171.4, 96.0, 61.3, 60.9, 52.7, 42.8, 41.3, 34.1, 32.4, 30.8, 25.3, 14.4, 14.3 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 99:1), 1.0 mL/min; major enantiomer t_R = 15.1 min, minor enantiomer t_R = 26.4 min. HRMS (ESI) : [M⁺] calcd for [C₁₈H₂₂O₆]: 310.1416, found: 310.1416.

22b: (3aS,4S,5R,7aR)-diethyl 4-formyl-7-hydroxy-2,3,3a,4,5,7a-hexahydro-1H-indene-5,6-dicarboxylate




colorless oil. $[\alpha]_D^{24} = -18.8 (c \ 1.00, CH_2Cl_2, 98\% ee); IR (thin film, KBr): 2979, 1728, 1654, 1616, 1234, 1183, 1033 cm⁻¹; ¹H NMR (400 MHz, CDCl_3) <math>\delta$ 12.55 (s, 1H), 9.76 (d, *J* = 2.2 Hz, 1H), 4.10-4.27 (m, 4H), 3.82 (dd, *J* = 8.9, 1.5 Hz, 1H), 2.87 (m, 2H), 2.56 (m, 1H), 1.98 (m, 1H), 1.86 (m, 1H), 1.79 (m, 1H), 1.65 (m, 2H), 1.49 (m, 1H), 1.27 (t, *J* = 7.1 Hz, 3H), 1.25 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl_3) δ 201.8, 174.8, 174.1, 171.7, 95.2, 61.2, 61.0, 51.1, 43.1, 38.8, 38.0, 29.1, 25.7, 24.0, 14.3, 14.2 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 1.0 mL/min; minor enantiomer t_R = 29.2 min, major enantiomer t_R = 39.5 min. HRMS (ESI) : [M⁺] calcd for [C₁₆H₂₂O₆]: 310.1416, found: 310.1422.

23a: (3aR,6S,7R,7aS)-methyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate



white powder. m.p.: 104-107 °C. $[\alpha]_D^{23}$ = +194.4 (*c* 1.00, CH₂Cl₂, 97% ee); IR (thin film, KBr): 2955, 2870, 1722, 1653, 1614, 1520, 1442, 1349, 1246, 856, 824, 736, 707 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.50 (s, 1H), 9.39 (d, *J* = 1.3 Hz, 1H), 8.13 (d, *J* = 8.6 Hz, 2H), 7.25 (d, *J* = 8.6 Hz, 2H), 4.45 (d, *J* = 3.8 Hz, 1H), 3.60 (s, 3H), 2.98 (m, 1H), 2.57 (m, 2H), 2.33 (m, 1H), 2.05 (m, 1H), 1.80 (m, 1H), 1.63 (m, 2H), 1.32 (m, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 203.1, 176.3, 171.7, 147.5, 147.3, 129.8, 123.7, 99.0, 54.7, 52.0, 43.2, 41.3, 32.4, 31.7, 31.3, 25.1 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 95:5), 1.0 mL/min; major enantiomer t_R = 18.4 min, minor enantiomer t_R = 27.4 min. HRMS (ESI) : [M⁺] calcd for [C₁₈H₁₉NO₆]: 345.1212, found: 345.1218.


23b: (3aR,6S,7S,7aS)-methyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-2,3,3a,6,7,7a-hexahydro-1H-indene-5-carboxylate



colorless amorphous solid. $[\alpha]_D^{24}$ = +73.8 (*c* 0.500, CH₂Cl₂, 98% ee); IR (thin film, KBr): 2955, 1721, 1652, 1519, 1441, 1348, 1237, 1109, 832 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.58 (s, 1H),


9.68 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.8 Hz, 2H), 4.36 (d, J = 6.6 Hz, 1H), 3.49 (s, 3H), 2.97 (q, J = 7.4 Hz, 1H), 2.74 (m, 1H), 2.54 (m, 1H), 2.12 (m, 1H), 1.87 (m, 1H), 1.58-1.76 (m, 4H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 201.4, 175.1, 172.1, 152.5, 146.8, 128.8, 123.8, 97.9, 56.4, 51.7, 43.4, 37.9, 36.5, 29.8, 26.5, 24.0 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 99:1), 1.0 mL/min; major enantiomer $t_R = 46.6$ min, minor enantiomer $t_R = 52.3$ min. HRMS (ESI) : [M⁺] calcd for [C₁₈H₁₉NO₆]: 345.1212, found: 345.1216.

24a: (3aR,6S,7S,7aR)-ethyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-1,3,3a,6,7,7ahexahydrobenzo[c]thiophene-5-carboxylate



yellow crystals. m.p.: 180-183 °C. $[\alpha]_D^{22}$ = +86.7 (*c* 1.00, CH₂Cl₂, 98% ee); IR (thin film, KBr): 2927, 1654, 1519, 1350, 1248, 1225, 857, 707 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.54 (s, 1H), 9.48 (d, *J* = 0.8 Hz, 1H), 8.15 (d, *J* = 8.4 Hz, 2H), 7.27 (d, *J* = 8.4 Hz, 2H), 4.53 (m, 1H), 4.04 (m, 2H), 3.45 (dd, *J* = 11.3, 8.6 Hz, 1H), 3.24 (m, 2H), 3.00 (d, *J* = 1.5 Hz, 2H), 2.91 (dd, *J* = 11.3, 9.7 Hz, 1H), 2.71 (d, *J* = 12.1 Hz, 1H), 1.03 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 201.5, 173.0, 171.0, 147.4, 147.2, 129.8, 123.8, 98.8, 61.2, 50.8, 46.4, 40.9, 36.7, 36.2, 35.6, 14.0 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (*n*-hexane: *i*-PrOH = 90:10), 1.0 mL/min; major enantiomer t_R = 22.7 min, minor enantiomer t_R = 35.7 min. HRMS (ESI) : [M] calcd for [C₁₈H₁₉NO₆S]: 377.0933, found: 377.0938.

24b: (3aR,6S,7R,7aR)-ethyl 7-formyl-4-hydroxy-6-(4-nitrophenyl)-1,3,3a,6,7,7ahexahydrobenzo[c]thiophene-5-carboxylate





colorless crystals. m.p.: 101-104 °C. $[\alpha]_D^{23}$ = +46.8 (*c* 1.00, CH₂Cl₂, 96% ee); IR (thin film, KBr): 2937, 1721, 1651, 1518, 1348, 1237, 848, 736 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 12.76 (s, 1H), 9.79 (d, *J* = 0.9 Hz, 1H), 8.14 (d, *J* = 8.6 Hz, 2H), 7.37 (d, *J* = 8.7 Hz, 2H), 4.45 (d, *J* = 7.0 Hz, 1H), 3.97 (m, 2H), 3.40 (q, *J* = 4.5 Hz, 1H), 3.21 (d, *J* = 5.9 Hz, 2H), 2.99 (m, 2H), 2.82-2.90 (m, 2H), 0.90 (t, *J* = 7.2 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 199.7, 171.4, 171.0, 152.5, 146.9, 128.8, 123.9, 98.8, 61.1, 55.9, 47.1, 40.4, 37.4, 32.9, 31.6, 13.8 ppm; the enantiomeric excess was determined by HPLC with an AD-H column (*n*-hexane: *i*-PrOH = 90:10), 1.0 mL/min; major enantiomer t_R = 20.2 min, minor enantiomer t_R = 25.2 min. HRMS (ESI) : [M] calcd for [C₁₈H₁₉NO₆S]: 377.0933, found: 377.0940.


References


- 1. Ibrahem, I.; Cordova, A. *Chem. Commun.* **2006**, 1760-1762.
- 2. Hayashi, Y.; Gotoh, H.; Hayashi, T.; Shoji, M. Angew. Chem. Int. Ed. 2005, 44, 4212-4215.


- 3. Mathre, D.; Jones, T.; Xavier, L.; Blacklock, T.; Reamer, R.; Mohan, J.; Jones, E.; Turner, T.; Hoogsteen, K.; Baum, M.; Grabowski, E. *J. Org. Chem.* **1991**, *56*, 751-762.
- 4. Battistuzzi, G.; Cacchi, S.; Fabrizi, G. Org. Lett. 2003, 5, 777-780.
- 5. Stoll, M.; Flament, I. Helv. Chim. Acta 1969, 52, 1996-2003.
- 6. Beagley, B.; Larsen, D.; Pritchard, R.; Stoodley, R.; Whiting, A. *J. Chem. Soc., Perkin Trans. 1* **1989**, *6*, 1127-1137.
- 7. Johnson, J.; Evanoff, D.; Savard, M.; Lange, G.; Ramadhar, T.; Assoud, A.; Taylor, N.; Dmitrienko, G. *J. Org. Chem.* **2008**, *73*, 6970-6982.



































S24


23.87





45.53








S28


29.99


25.52



















15.06






































52.10

44.54

